During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by proceeding directly to chemotherapy along with ADT.

Recently, I found out that men in the United Kingdom (UK) were having difficulty getting this early chemotherapy since it is only approved for men who have become castrate resistant. To say that this is frustrating would be an understatement.

I am wondering if men in other counties are having a similar experience? I have the interest of some media people so I am hoping to hear from anyone who has either had this difficulty or has had the cooperation of their insurance company.